Description:SARS-CoV-2 B.1.351 Variant (South Africa) Spike RBD (K417N/E484K/N501Y) Mutant Protein
Product: Recombinant protein of receptor binding domain (RBD, Arg319-Phe541) of severe acute respiratory syndrome coronavirus 2 South Africa variant (SARS-CoV-2 variant B.1.351, RBD K417N, E484K, N501Y, NC_045512.2), with a polyhistidine tag
Cat #: LTP-V020
Host: Human 293 cells
RefSeq: NC_045512.2/MN908947.5; YP_009724390.1/QHD43416.3; UniProt#: P0DTC2; GeneID: 43740570;
Applications: Antigens, Western, ELISA and other in vitro binding or in vivo functional assays, and protein-protein interaction studies; For research & development use only!
Background: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV-2 spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S RBD protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV-2 (2019-nCoV) as in the recent COVID-19 outbreak. Spike S1 mainly contains an N-terminal domain (NTD) and a receptor-binding domain (RBD) that recognizes a variety of host cell surface receptors.
Quantity: 50ug, Endotoxin level is < 0.1 ng/µg of protein (<1EU/µg).
Purity: >90% by SDS-PAGE gel and Coomassie Blue staining
Formulation: Purified protein formulated in a sterile solution of PBS buffer, pH7.2, without any preservatives